PLN 32.2
(1.58%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -73.01 Million PLN | -108.84% |
2022 | -38.36 Million PLN | -20.99% |
2021 | -31.7 Million PLN | -159.56% |
2020 | -12.21 Million PLN | -55.52% |
2019 | -7.85 Million PLN | -90.19% |
2018 | -4.13 Million PLN | -3005.26% |
2017 | -133 Thousand PLN | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | -9.72 Million PLN | 41.57% |
2024 Q2 | -10.75 Million PLN | -4.11% |
2023 Q4 | -16.63 Million PLN | -2.29% |
2023 Q1 | -15.45 Million PLN | -88.63% |
2023 Q3 | -16.26 Million PLN | 45.27% |
2023 FY | -80.12 Million PLN | -108.84% |
2023 Q2 | -29.72 Million PLN | -92.29% |
2022 Q2 | -9.99 Million PLN | 7.89% |
2022 FY | -38.36 Million PLN | -20.99% |
2022 Q4 | -8.19 Million PLN | 12.08% |
2022 Q3 | -9.32 Million PLN | 6.77% |
2022 Q1 | -10.85 Million PLN | -0.39% |
2021 Q2 | -6.91 Million PLN | -32.64% |
2021 Q4 | -10.81 Million PLN | -23.3% |
2021 Q3 | -8.76 Million PLN | -26.78% |
2021 FY | -31.7 Million PLN | -159.56% |
2021 Q1 | -5.21 Million PLN | -248.06% |
2020 FY | -12.21 Million PLN | -55.52% |
2020 Q3 | -6.23 Million PLN | 0.0% |
2020 Q4 | -1.49 Million PLN | 75.96% |
2019 FY | -7.85 Million PLN | -90.19% |
2018 FY | -4.13 Million PLN | -3005.26% |
2017 FY | -133 Thousand PLN | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Bioceltix S.A. | -15.81 Million PLN | -361.555% |
BIOTON S.A. | 15.29 Million PLN | 577.385% |
Mabion S.A. | 55.06 Million PLN | 232.609% |
Molecure S.A. | -22.1 Million PLN | -230.334% |
NanoGroup S.A. | -7.9 Million PLN | -824.03% |
Pharmena S.A. | 34.87 Million PLN | 309.389% |
Poltreg S.A. | -16.86 Million PLN | -333.021% |
Pure Biologics Spólka Akcyjna | -31.71 Million PLN | -130.204% |
Ryvu Therapeutics S.A. | -100.94 Million PLN | 27.67% |
Synthaverse S.A. | 8.64 Million PLN | 944.408% |
Urteste S.A. | -6.44 Million PLN | -1032.558% |